Innovent Commences Patient Dosing in GLORY-2 Phase 3 Study

Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in a phase 3 clinical trial of higher dose 9 mg mazdutide (Innovent R&D Code: IBI362) , a glucagon-like peptide 1 receptor and glucagon receptor dual agonist, in Chinese adults with obesity.  

The primary objectives are the percentage change in body weight from baseline to week 60, as well as the proportion of participants who lost 5% or more of their body weight from baseline at week 60. A phase 2 research in Chinese persons with obesity with a BMI of 30 kg/m2 (NCT04904913) found that mazdutide 9mg achieved an 18.6% placebo-adjusted mean percent reduction in body weight after 48 weeks of treatment. 

Furthermore, mazdutide reduced waist circumference, blood pressure, lipids, serum uric acid, transaminase and liver fat, bringing multiple metabolic benefits to the subjects. Mazdutide was well tolerated and the overall safety profile was similar to other GLP-1 class drugs, with no new safety signals observed, as per pharmabiz.

China has the world's highest population of overweight or obese people, and the obesity rate is expected to rise. Obesity can cause a number of issues or diseases that reduce life expectancy and lower quality of life. Overweight and obese deaths accounted for 11.1% of chronic noncommunicable disease deaths in 2019, a considerable rise from 5.7% in 1990. Obesity is a chronic disease that requires long-term management, and in China, there is a scarcity of long-term effective and safe treatments. For individuals who are overweight or obese, lifestyle management is the first and most important therapeutic option.